Temat: "Muscarinic Antagonists" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and β 2 Adrenergic Receptor Agonist Navafenterol in Human Small Airways.
Autorzy:: Jude JA; Pharmacology & Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.; Rutgers Institute for Translational Medicine & Science (RITMS), Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
Dainty I; Bioscience, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, 431 83 Molndal, Sweden.
Karmacharya N; Rutgers Institute for Translational Medicine & Science (RITMS), Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
Jester W; Rutgers Institute for Translational Medicine & Science (RITMS), Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
Panettieri R; Rutgers Institute for Translational Medicine & Science (RITMS), Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.; Pokaż więcej
Źródło:: Cells [Cells] 2023 Jan 06; Vol. 12 (2). Date of Electronic Publication: 2023 Jan 06.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Bronchodilator Agents*/pharmacology
Pulmonary Disease, Chronic Obstructive*/drug therapy
Humans ; Muscarinic Antagonists/pharmacology ; Histamine/pharmacology ; Propranolol/pharmacology ; Lung ; Receptors, Muscarinic ; Adrenergic Agonists/pharmacology ; Adrenergic Agonists/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Autorzy:: Usmani O; Asthma Lab, National Heart and Lung Institute (NHLI), Imperial College London & Royal Brompton Hospital, South Block, Royal Brompton Campus, Sydney St, Chelsea, London, SW3 6NP, UK. .
Roche N; Respiratory Medicine, Hôpital Cochin (AP-HP), University of Paris, Cochin Institute, Paris, France.
Wahab E; Simbec Research Ltd, Merthyr Tydfil, UK.
Israel S; Simbec Research Ltd, Merthyr Tydfil, UK.
Jenkins M; AstraZeneca, Cambridge, UK.
Trivedi R; AstraZeneca, Durham, NC, USA.
Dorinsky P; AstraZeneca, Durham, NC, USA.
Aurivillius M; AstraZeneca, Gothenburg, Sweden.; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2021 Oct 07; Vol. 22 (1), pp. 261. Date of Electronic Publication: 2021 Oct 07.
Typ publikacji:: Clinical Trial, Phase I; Journal Article
MeSH Terms:: Adrenergic beta-2 Receptor Agonists*/administration & dosage
Adrenergic beta-2 Receptor Agonists*/adverse effects
Bronchodilator Agents*/administration & dosage
Bronchodilator Agents*/adverse effects
Glucocorticoids*/administration & dosage
Glucocorticoids*/adverse effects
Lung*/diagnostic imaging
Lung*/drug effects
Lung*/physiopathology
Muscarinic Antagonists*/administration & dosage
Muscarinic Antagonists*/adverse effects
Pulmonary Disease, Chronic Obstructive*/diagnostic imaging
Pulmonary Disease, Chronic Obstructive*/drug therapy
Pulmonary Disease, Chronic Obstructive*/physiopathology
Aged ; Female ; Humans ; Male ; Middle Aged ; Administration, Inhalation ; Contrast Media ; Metered Dose Inhalers ; Predictive Value of Tests ; Radionuclide Imaging ; Recovery of Function ; Severity of Illness Index ; Sodium Pertechnetate Tc 99m ; Time Factors ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
Autorzy:: Vogelmeier CF; Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-Universität Marburg, German Centre for Lung Research (DZL), Baldingerstraße, 35043, Marburg, Germany. .
Jones PW; GSK, Brentford, Middlesex, UK.
Kerwin EM; Altitude Clinical Consulting and Clinical Research Institute of Southern Oregon, Medford, OR, USA.
Boucot IH; GSK, Brentford, Middlesex, UK.
Maltais F; Centre de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada.
Tombs L; Precise Approach Ltd, GSK, Brentford, Middlesex, UK.
Compton C; GSK, Brentford, Middlesex, UK.
Lipson DA; Respiratory Clinical Sciences, GSK, Collegeville, PA, USA.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Bjermer LH; Respiratory Medicine and Allergology, Lund University, Lund, Sweden.; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2021 Oct 28; Vol. 22 (1), pp. 279. Date of Electronic Publication: 2021 Oct 28.
Typ publikacji:: Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Adrenergic beta-2 Receptor Agonists/*administration & dosage
Benzyl Alcohols/*administration & dosage
Bronchodilator Agents/*administration & dosage
Chlorobenzenes/*administration & dosage
Lung/*drug effects
Muscarinic Antagonists/*administration & dosage
Pulmonary Disease, Chronic Obstructive/*drug therapy
Quinuclidines/*administration & dosage
Adrenergic beta-2 Receptor Agonists/adverse effects ; Aged ; Benzyl Alcohols/adverse effects ; Bronchodilator Agents/adverse effects ; Chlorobenzenes/adverse effects ; Double-Blind Method ; Drug Combinations ; Female ; Forced Expiratory Volume ; Humans ; Lung/physiopathology ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Quinuclidines/adverse effects ; Recovery of Function ; Time Factors ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: The Spasmolytic, Bronchodilator, and Vasodilator Activities of Parmotrema perlatum Are Explained by Anti-Muscarinic and Calcium Antagonistic Mechanisms.
Autorzy:: Hussain M; Faculty of Pharmacy, The Islamia University of Bahawulpur, Bahawulpur 63100, Pakistan.
Bakhsh H; Faculty of Pharmacy, Bahauddin Zakariya University, Multan 66000, Pakistan.
Syed SK; Department of Basic Medical Sciences, School of Health Sciences, University of Management and Technology, Lahore 54000, Pakistan.
Ullah MS; Department of Pharmaceutical Chemistry, Government College University, Faisalabad 38000, Pakistan.
Alqahtani AM; Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.
Alqahtani T; Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.
Aldahish AA; Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.
Emran TB; Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh.
Rehman KU; Faculty of Pharmacy, The Islamia University of Bahawulpur, Bahawulpur 63100, Pakistan.
Janbaz KH; Faculty of Pharmacy, Bahauddin Zakariya University, Multan 66000, Pakistan.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2021 Oct 20; Vol. 26 (21). Date of Electronic Publication: 2021 Oct 20.
Typ publikacji:: Journal Article
MeSH Terms:: Biological Products/*pharmacology
Bronchodilator Agents/*pharmacology
Calcium Channel Blockers/*pharmacology
Muscarinic Antagonists/*pharmacology
Parasympatholytics/*pharmacology
Parmeliaceae/*chemistry
Vasodilator Agents/*pharmacology
Animals ; Biological Products/chemistry ; Bronchodilator Agents/chemistry ; Calcium Channel Blockers/chemistry ; Chromatography, High Pressure Liquid ; Dose-Response Relationship, Drug ; Mice ; Molecular Structure ; Muscarinic Antagonists/chemistry ; Parasympatholytics/chemistry ; Spectrum Analysis ; Toxicity Tests, Acute ; Vasodilator Agents/chemistry
SCR Organism:: Parmotrema perlatum

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
Autorzy:: Zheng J; State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Baldi S; Global Clinical Development, Chiesi Farmaceutici SpA, Largo Belloli, 11\a, 43122, Parma, Italy.
Zhao L; Shengjing Hospital of China Medical University, Shenyang, China.
Li H; Shanghai Pulmonary Hospital, Shanghai, China.
Lee KH; Yeungnam University Medical Center, Daegu, Republic of Korea.
Singh D; Medicines Evaluation Unit, The University of Manchester, Manchester University NHS Foundations Trust, Manchester, UK.
Papi A; Respiratory Medicine Unit, University of Ferrara, University Hospital S. Anna, Ferrara, Italy.
Grapin F; Global Clinical Development, Chiesi Farmaceutici SpA, Largo Belloli, 11\a, 43122, Parma, Italy.
Guasconi A; Global Clinical Development, Chiesi Farmaceutici SpA, Largo Belloli, 11\a, 43122, Parma, Italy.
Georges G; Global Clinical Development, Chiesi Farmaceutici SpA, Largo Belloli, 11\a, 43122, Parma, Italy. .; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2021 Mar 23; Vol. 22 (1), pp. 90. Date of Electronic Publication: 2021 Mar 23.
Typ publikacji:: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Adrenergic beta-2 Receptor Agonists/*administration & dosage
Beclomethasone/*administration & dosage
Bronchodilator Agents/*administration & dosage
Formoterol Fumarate/*administration & dosage
Glucocorticoids/*administration & dosage
Glycopyrrolate/*administration & dosage
Lung/*drug effects
Muscarinic Antagonists/*administration & dosage
Pulmonary Disease, Chronic Obstructive/*drug therapy
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Aged ; Beclomethasone/adverse effects ; Bronchodilator Agents/adverse effects ; China ; Disease Progression ; Double-Blind Method ; Drug Combinations ; Dry Powder Inhalers ; Female ; Forced Expiratory Volume ; Formoterol Fumarate/adverse effects ; Glucocorticoids/adverse effects ; Glycopyrrolate/adverse effects ; Humans ; Lung/physiopathology ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Recovery of Function ; Republic of Korea ; Taiwan ; Time Factors ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD.
Autorzy:: Dean J; Medicines Evaluation Unit, Southmoor Road, Manchester, M23 9QZ, UK. .
Panainte C; Medicines Evaluation Unit, Southmoor Road, Manchester, M23 9QZ, UK.
Khan N; Medicines Evaluation Unit, Southmoor Road, Manchester, M23 9QZ, UK.
Singh D; Medicines Evaluation Unit, Southmoor Road, Manchester, M23 9QZ, UK.; Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2020 Dec 09; Vol. 21 (1), pp. 323. Date of Electronic Publication: 2020 Dec 09.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Adrenergic beta-2 Receptor Agonists/*administration & dosage
Beclomethasone/*administration & dosage
Bronchodilator Agents/*administration & dosage
Formoterol Fumarate/*administration & dosage
Glucocorticoids/*administration & dosage
Glycopyrrolate/*administration & dosage
Lung/*drug effects
Muscarinic Antagonists/*administration & dosage
Pulmonary Disease, Chronic Obstructive/*drug therapy
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Adult ; Aged ; Beclomethasone/adverse effects ; Bronchodilator Agents/adverse effects ; Cross-Over Studies ; Drug Combinations ; England ; Female ; Forced Expiratory Volume ; Formoterol Fumarate/adverse effects ; Glucocorticoids/adverse effects ; Glycopyrrolate/adverse effects ; Humans ; Lung/physiopathology ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Nebulizers and Vaporizers ; Particle Size ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Recovery of Function ; Time Factors ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator.
Autorzy:: Jimenez E; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, 08020, Barcelona, Spain. .
Astbury C; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Albayaty M; Early Phase Clinical Unit, PAREXEL International GmbH, Harrow, UK.
Wählby-Hamrén U; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Seoane B; Biometrics and Information Sciences, Late-Stage Development, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Villarroel C; Late-Stage Development, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Pujol H; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Bermejo MJ; Patient Safety, Chief Medical Office, R&D, AstraZeneca, Barcelona, Spain.
Aggarwal A; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Psallidas I; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2020 Sep 09; Vol. 21 (Suppl 1), pp. 211. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
MeSH Terms:: Adrenergic beta-2 Receptor Agonists/*administration & dosage
Asthma/*drug therapy
Bronchoconstriction/*drug effects
Bronchodilator Agents/*administration & dosage
Lung/*drug effects
Muscarinic Antagonists/*administration & dosage
Quinolines/*administration & dosage
Triazoles/*administration & dosage
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Adrenergic beta-2 Receptor Agonists/pharmacokinetics ; Adult ; Asthma/diagnosis ; Asthma/physiopathology ; Bronchodilator Agents/adverse effects ; Bronchodilator Agents/pharmacokinetics ; England ; Female ; Forced Expiratory Volume ; Humans ; Lung/physiopathology ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Muscarinic Antagonists/pharmacokinetics ; Quinolines/adverse effects ; Quinolines/pharmacokinetics ; Recovery of Function ; Severity of Illness Index ; Single-Blind Method ; Treatment Outcome ; Triazoles/adverse effects ; Triazoles/pharmacokinetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies.
Autorzy:: Balaguer V; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Albayaty M; the Early Phase Clinical Unit, PAREXEL International GmbH, Harrow, UK.
Jimenez E; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain.
Wählby-Hamrén U; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Astbury C; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Seoane B; Biometrics and Information Sciences, Late Stage Development, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Malice MP; Early Biostats and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Lei A; Patient Safety RIA, Chief Medical Office, R&D, AstraZeneca, Barcelona, Spain.
Aggarwal A; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.
Psallidas I; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. .; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2020 Sep 09; Vol. 21 (Suppl 1), pp. 212. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
MeSH Terms:: Adrenergic beta-2 Receptor Agonists/*administration & dosage
Bronchodilator Agents/*administration & dosage
Muscarinic Antagonists/*administration & dosage
Quinolines/*administration & dosage
Triazoles/*administration & dosage
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Adrenergic beta-2 Receptor Agonists/pharmacokinetics ; Adult ; Asian People ; Bronchodilator Agents/adverse effects ; Bronchodilator Agents/pharmacokinetics ; Healthy Volunteers ; Humans ; Japan/ethnology ; London ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Muscarinic Antagonists/pharmacokinetics ; Quinolines/adverse effects ; Quinolines/pharmacokinetics ; Single-Blind Method ; Triazoles/adverse effects ; Triazoles/pharmacokinetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.
Autorzy:: Singh D; The Medicines Evaluation Unit, Centre for Respiratory and Allergy Medicine, University of Manchester, University Hospital of South Manchester NHS Foundation Trust, M23 9QZ, Manchester, UK. .
Balaguer V; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Astbury C; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Wählby-Hamrén U; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Jimenez E; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain.
Seoane B; Biometrics and Information Sciences, Late-Stage Development, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Villarroel C; Late-Stage Development, BioPharmaceuticals R&D; AstraZeneca, Barcelona, Spain.
Lei A; Patient Safety RIA, Chief Medical Office, R&D, AstraZeneca, Barcelona, Spain.
Aggarwal A; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.
Psallidas I; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2020 Sep 09; Vol. 21 (Suppl 1), pp. 102. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
MeSH Terms:: Adrenergic beta-2 Receptor Agonists/*administration & dosage
Bronchoconstriction/*drug effects
Bronchodilator Agents/*administration & dosage
Lung/*drug effects
Muscarinic Antagonists/*administration & dosage
Pulmonary Disease, Chronic Obstructive/*drug therapy
Quinolines/*administration & dosage
Triazoles/*administration & dosage
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Adrenergic beta-2 Receptor Agonists/pharmacokinetics ; Aged ; Bronchodilator Agents/adverse effects ; Bronchodilator Agents/pharmacokinetics ; Cross-Over Studies ; Double-Blind Method ; England ; Female ; Forced Expiratory Volume ; Humans ; Lung/physiopathology ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Muscarinic Antagonists/pharmacokinetics ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Quinolines/adverse effects ; Quinolines/pharmacokinetics ; Recovery of Function ; Treatment Outcome ; Triazoles/adverse effects ; Triazoles/pharmacokinetics ; Vital Capacity

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Regional lung deflation with increased airway volume underlies the functional response to bronchodilators in chronic obstructive pulmonary disease.
Autorzy:: Tanabe N; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Sato S; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Muro S; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.; Department of Respiratory Medicine, Nara Medical University, Nara, Japan.
Shima H; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Oguma T; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tanimura K; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Sato A; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hirai T; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.; Pokaż więcej
Źródło:: Physiological reports [Physiol Rep] 2019 Dec; Vol. 7 (24), pp. e14330.
Typ publikacji:: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Pulmonary Ventilation*
Bronchodilator Agents/*pharmacology
Lung/*drug effects
Lung Diseases, Obstructive/*physiopathology
Muscarinic Antagonists/*pharmacology
Aged ; Aged, 80 and over ; Bronchodilator Agents/therapeutic use ; Female ; Humans ; Lung/diagnostic imaging ; Lung/physiopathology ; Lung Diseases, Obstructive/diagnostic imaging ; Lung Diseases, Obstructive/drug therapy ; Lung Volume Measurements ; Male ; Muscarinic Antagonists/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
Autorzy:: Langham S; Maverex Limited, Manchester, UK. .
Lewis J; Maverex Limited, Manchester, UK.
Pooley N; Maverex Limited, Manchester, UK.
Embleton N; Maverex Limited, Manchester, UK.
Langham J; Maverex Limited, Manchester, UK.
Han MK; University of Michigan, Women's Respiratory Clinic, Ann Arbor, USA.
Chalmers JD; University of Dundee and Ninewells Hospital and Medical School, Dundee, UK.; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2019 Nov 04; Vol. 20 (1), pp. 242. Date of Electronic Publication: 2019 Nov 04.
Typ publikacji:: Journal Article; Systematic Review
MeSH Terms:: Adrenal Cortex Hormones/*administration & dosage
Adrenergic beta-2 Receptor Agonists/*administration & dosage
Bronchodilator Agents/*administration & dosage
Lung/*drug effects
Muscarinic Antagonists/*administration & dosage
Pulmonary Disease, Chronic Obstructive/*drug therapy
Administration, Inhalation ; Adrenal Cortex Hormones/adverse effects ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Aged ; Bronchodilator Agents/adverse effects ; Disease Progression ; Drug Therapy, Combination ; Female ; Humans ; Lung/physiopathology ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Nebulizers and Vaporizers ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Randomized Controlled Trials as Topic ; Recovery of Function ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Effects of (a Combination of) the Beta 2 -Adrenoceptor Agonist Indacaterol and the Muscarinic Receptor Antagonist Glycopyrrolate on Intrapulmonary Airway Constriction.
Autorzy:: Maarsingh H; Department of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL 33416, USA.
Oldenburger A; Department of Molecular Pharmacology, University of Groningen, 9713 AV Groningen, The Netherlands.; Groningen Research Institute of Pharmacy, University of Groningen, 9713 AW Groningen, The Netherlands.; Groningen Research Institute of Asthma and COPD, University of Groningen, University Medical Center Groningen, 9713 AV Groningen, The Netherlands.
Han B; Department of Molecular Pharmacology, University of Groningen, 9713 AV Groningen, The Netherlands.; Groningen Research Institute of Pharmacy, University of Groningen, 9713 AW Groningen, The Netherlands.; Groningen Research Institute of Asthma and COPD, University of Groningen, University Medical Center Groningen, 9713 AV Groningen, The Netherlands.
Zuidhof AB; Department of Molecular Pharmacology, University of Groningen, 9713 AV Groningen, The Netherlands.; Groningen Research Institute of Pharmacy, University of Groningen, 9713 AW Groningen, The Netherlands.
Elzinga CRS; Department of Molecular Pharmacology, University of Groningen, 9713 AV Groningen, The Netherlands.; Groningen Research Institute of Pharmacy, University of Groningen, 9713 AW Groningen, The Netherlands.
Timens W; Groningen Research Institute of Asthma and COPD, University of Groningen, University Medical Center Groningen, 9713 AV Groningen, The Netherlands.; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Meurs H; Department of Molecular Pharmacology, University of Groningen, 9713 AV Groningen, The Netherlands.; Groningen Research Institute of Pharmacy, University of Groningen, 9713 AW Groningen, The Netherlands.; Groningen Research Institute of Asthma and COPD, University of Groningen, University Medical Center Groningen, 9713 AV Groningen, The Netherlands.
Sopi RB; Department of Molecular Pharmacology, University of Groningen, 9713 AV Groningen, The Netherlands.; Groningen Research Institute of Pharmacy, University of Groningen, 9713 AW Groningen, The Netherlands.; Department of Premedical Courses, Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo.
Schmidt M; Department of Molecular Pharmacology, University of Groningen, 9713 AV Groningen, The Netherlands.; Groningen Research Institute of Pharmacy, University of Groningen, 9713 AW Groningen, The Netherlands.; Groningen Research Institute of Asthma and COPD, University of Groningen, University Medical Center Groningen, 9713 AV Groningen, The Netherlands.; Pokaż więcej
Źródło:: Cells [Cells] 2021 May 18; Vol. 10 (5). Date of Electronic Publication: 2021 May 18.
Typ publikacji:: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Adrenergic beta-2 Receptor Agonists/*pharmacology
Bronchoconstriction/*drug effects
Bronchodilator Agents/*pharmacology
Glycopyrrolate/*pharmacology
Indans/*pharmacology
Lung/*drug effects
Muscarinic Antagonists/*pharmacology
Pulmonary Disease, Chronic Obstructive/*drug therapy
Quinolones/*pharmacology
Animals ; Case-Control Studies ; Dose-Response Relationship, Drug ; Drug Synergism ; Drug Therapy, Combination ; Female ; Guinea Pigs ; Humans ; Lung/metabolism ; Lung/physiopathology ; Male ; Pulmonary Disease, Chronic Obstructive/metabolism ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Receptor, Muscarinic M3/antagonists & inhibitors ; Receptor, Muscarinic M3/metabolism ; Receptors, Adrenergic, beta-2/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
Autorzy:: Singh D; Medicines Evaluation Unit, The University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK. .
Virchow JC; Zentrum Für Innere Medizin, Abteilung Für Pneumologie, Universitätsmedizin Rostock, Rostock, Germany.
Canonica GW; Center of Personalized Medicine: Asthma and Allergy, Humanitas University and Research Hospital IRCCS, Milan, Italy.
Vele A; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Kots M; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Georges G; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Papi A; Respiratory Medicine Unit, University of Ferrara, University Hospital S.Anna, Ferrara, Italy.; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2020 Oct 29; Vol. 21 (1), pp. 285. Date of Electronic Publication: 2020 Oct 29.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Asthma/*drug therapy
Beclomethasone/*administration & dosage
Bronchodilator Agents/*administration & dosage
Formoterol Fumarate/*administration & dosage
Glycopyrrolate/*administration & dosage
Muscarinic Antagonists/*administration & dosage
Administration, Inhalation ; Adult ; Aged ; Asthma/diagnosis ; Asthma/physiopathology ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy.
Autorzy:: Calverley PMA; Clinical Science Centre, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
Hoz A; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Xue W; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Ferguson GT; Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA.
Miravitlles M; Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Research Institute (VHIR), CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.; Pokaż więcej
Źródło:: COPD [COPD] 2020 Oct; Vol. 17 (5), pp. 477-484. Date of Electronic Publication: 2020 Sep 15.
Typ publikacji:: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Benzoxazines/*therapeutic use
Bronchodilator Agents/*therapeutic use
Muscarinic Antagonists/*therapeutic use
Pulmonary Disease, Chronic Obstructive/*drug therapy
Tiotropium Bromide/*therapeutic use
Administration, Inhalation ; Adrenal Cortex Hormones/administration & dosage ; Aged ; Drug Combinations ; Female ; Forced Expiratory Volume ; Humans ; Male ; Middle Aged ; Pulmonary Disease, Chronic Obstructive/complications ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: The Relaxant Effect of Plantago Major on Rat Tracheal Smooth Muscles and Its Possible Mechanisms.
Autorzy:: Boskabadi J; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran AND Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. .
Saadat S; Department of Physiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran. .
Boskabady MH; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran AND Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. .; Pokaż więcej
Źródło:: Iranian journal of allergy, asthma, and immunology [Iran J Allergy Asthma Immunol] 2020 Aug 25; Vol. 19 (4), pp. 386-396. Date of Electronic Publication: 2020 Aug 25.
Typ publikacji:: Journal Article
MeSH Terms:: Bronchodilator Agents/*pharmacology
Muscle, Smooth/*drug effects
Plant Extracts/*pharmacology
Plantago/*drug effects
Trachea/*drug effects
Animals ; Bronchodilator Agents/chemistry ; Dose-Response Relationship, Drug ; Histamine H1 Antagonists/pharmacology ; Muscarinic Antagonists/pharmacology ; Muscle Relaxation/drug effects ; Muscle, Smooth/metabolism ; Plant Extracts/chemistry ; Rats ; Receptors, Histamine H1/metabolism ; Receptors, Muscarinic/metabolism ; Trachea/metabolism